Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Enclomiphene | Testosterone Propionate | |
|---|---|---|
| Category | Hormones | Hormones |
| Standard Dose | Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism. | Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection. |
| Timing | Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation. | Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation. |
| Cycle Duration | Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months. | Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden. |
| Evidence Level | moderate_human | strong_human |
Enclomiphene is the purified trans-isomer of clomiphene citrate that acts as a selective estrogen receptor antagonist at the hypothalamus and pituitary without the estrogenic agonist activity of the zuclomiphene isomer. By blocking estrogen receptor alpha (ERa) in the hypothalamus, it removes estradiol-mediated negative feedback on GnRH neurons, resulting in increased pulsatile GnRH release and consequent elevation of LH and FSH from the anterior pituitary. This stimulates endogenous Leydig cell testosterone production while preserving spermatogenesis — a critical advantage over exogenous testosterone.
Research indicates 12.5-25 mg daily orally for testosterone restoration in secondary hypogonadism.
Once daily, morning preferred. No food timing requirements. Consistent daily dosing for optimal HPG axis stimulation.
Long-term use (months to years) is feasible due to absence of zuclomiphene accumulation issues. Reassess every 3-6 months.
Testosterone propionate is a short-acting esterified testosterone with a propionic acid ester, resulting in a half-life of approximately 0.8-1.5 days. Rapid hydrolysis by serum esterases produces a sharp testosterone spike followed by quick clearance. It activates the same androgen receptor-mediated genomic and non-genomic pathways as longer esters, but the pharmacokinetic profile demands frequent dosing. The short duration makes it useful for rapid onset situations and fine-tuned dose titration.
Research indicates 25-50 mg administered every other day or 50-100 mg every 2-3 days via intramuscular or subcutaneous injection.
Every-other-day or daily injection required due to short half-life. Rotate injection sites to minimize tissue irritation.
Short cycles (4-8 weeks) or as bridge therapy. Not typically used for long-term TRT due to injection frequency burden.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →